Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciencesPCRX -0.81%80 Days Sales Outstanding is 61.19 as of Jun. 2026, which is 32% above its 10-year median of 46.53. GuruFocus rates PCRX with a GF Score™ of 80/100 and a GF Value™ of $29.31 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 946 Drug Manufacturers companies, Pacira BioSciences ranks better than 62.26% on this metric.
Pacira BioSciences (NAS:PCRX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Pacira BioSciences Days Sales Outstanding Related Terms
Pacira BioSciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCRX vs AMPH, COLL, IRWD: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Days Sales Outstanding falls into.
Pacira BioSciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (PCRX) has a Days Sales Outstanding of 61.19 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Pacira BioSciences and its competitors. This is 32% above median its historical median of 46.53. Over the past decade, Pacira BioSciences' Days Sales Outstanding has ranged from 36.84 to 59.85. According to the industry distribution chart, Pacira BioSciences ranks #357 out of 946 companies in the Drug Manufacturers industry, placing it in the top 37.7%.
Is Pacira BioSciences' Days Sales Outstanding too high?
Pacira BioSciences' current Days Sales Outstanding of 61.19 is 32% above median its 10-year median of 46.53. Over the past 10 years, this metric has ranged from a low of 36.84 to a high of 59.85. The Drug Manufacturers industry median Days Sales Outstanding is 71.93. Pacira BioSciences' value of 61.19 is 14.9% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #357 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Days Sales Outstanding compare to AMPH and COLL?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #357 out of 946 companies for Days Sales Outstanding. This puts Pacira BioSciences in the upper half of its industry. The industry median Days Sales Outstanding is 71.93. Pacira BioSciences' value of 61.19 is 14.9% below this benchmark. Historically, Pacira BioSciences' own Days Sales Outstanding has ranged from 36.84 to 59.85 over the past decade. While the company's 10-year median is 46.53 vs. the industry median of 71.93, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.93, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Days Sales Outstanding of 61.19 is 14.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Days Sales Outstanding is 61.19, which is 32% above median its own 10-year median of 46.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.31, compared to a current price of $25.68 — trading 12.4% below its estimated fair value. The current Days Sales Outstanding is 61.19, which is 32% above median its 10-year median of 46.53 and 14.9% below the Drug Manufacturers industry median of 71.93. Pacira BioSciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Days Sales Outstanding is 61.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $25.68 is trading 12.4% below its estimated GF Value™ of $29.31.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
Days Sales Outstanding: 61.19 (32% above median its 10-year median of 46.53)
GF Value™: $29.31 vs. price of $25.68 (12.4% below fair value)
Industry Position: 14.9% below the Drug Manufacturers median (#357 of 946)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
80GF Score
Get the complete analysis for PCRX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
